Key Highlights

● Gossamer Bio's stock has crashed 95% this year, trading as a Penny Stock after a Phase 3 trial miss earlier in 2026.

● The company is racing toward a September 2026 deadline to file its New Drug Application for seralutinib.

● Seralutinib is an inhaled therapy for pulmonary arterial hypertension, and the upcoming NDA filing represents the company's next major catalyst.

● The scale of the stock's decline underscores how severely the market punished the earlier Phase 3 trial miss.

Gossamer Bio is racing toward a September 2026 deadline to file its New Drug Application for seralutinib, an inhaled therapy for pulmonary arterial hypertension (PAH), after a Phase 3 trial miss earlier this year nearly wiped out the stock. Shares now trade as a penny stock, down roughly 95% from their 52-week high near $3.87 to about $0.15, reflecting deep investor skepticism even after the FDA signaled in July that the trial's statistical shortfall might be a "review issue" rather than a fatal filing problem. The company reported second-quarter 2026 results on August 13-14, showing thinner cash reserves, a major Debt restructuring, and the reacquisition of full rights to seralutinib from former partner Chiesi. Whether the FDA ultimately accepts and approves the filing, and whether Gossamer has enough cash to get there, is now the whole Investment case.

Latest Development

On July 27, 2026, Gossamer disclosed it had held a Pre-NDA Type B meeting with the FDA in mid-June and received official minutes characterizing the statistical significance and treatment-effect magnitude from its pivotal PROSERA study as "review issues rather than filing issues." That gave the company a path to submit an NDA built on the single Phase 3 PROSERA trial plus supportive Phase 2 data, rather than requiring a second pivotal study. Shares jumped 42.9% on the news, per Simply Wall St. Gossamer simultaneously announced it was terminating its collaboration with Chiesi Pharmaceuticals and reacquiring full worldwide development and commercial rights to seralutinib, receiving a one-time $5 million payment from Chiesi, which retains only a capped sales Royalty and milestone payments going forward.

Q2 2026 results, released August 13-14, confirmed the September 2026 NDA submission timeline and disclosed a potential FDA approval decision in the third quarter of 2027 if the application is accepted for filing. The quarter also featured a large capital-structure move: Gossamer exchanged about $181.1 million of its 5.00% convertible notes due 2027 for $65.2 million of new 7.50% convertible secured notes due 2030, cutting total debt principal by roughly $115.9 million. Shareholders also approved a reverse stock split, expected to be executed in or after the third quarter, to address Nasdaq's minimum bid-price rule.

What the Numbers Show

Cash, cash equivalents, and marketable securities stood at $57.0 million as of June 30, 2026, down sharply from $136.9 million at year-end 2025. Management says that balance is sufficient to fund operations only into the first quarter of 2027, a runway that, notably, doesn't fully bridge to the Q3 2027 approval-decision timeline it just laid out, implying additional financing will likely be needed. Second-quarter R&D expense fell to $26.4 million from $41.6 million a year earlier as trial enrollment wound down; G&A was roughly flat at $8.9 million. Collaboration Revenue was $9.2 million, versus $11.5 million a year ago. GAAP Net Income was reported at $16.9 million for the quarter, versus a $38.3 million loss in Q2 2025, but that swing was driven almost entirely by a one-time $43.8 million gain on debt extinguishment from the note exchange, not underlying operations. (Some Earnings trackers instead cited a per-share loss versus consensus estimates, likely because analyst models hadn't priced in the one-time gain; investors should treat the headline "profit" as an accounting artifact of the debt swap, not a sign of operating improvement.) Shares outstanding have swelled to roughly 489 million after the note conversion, pushing market Capitalization to only about $75-87 million despite the large share count.

Why Investors Are Paying Attention

The stock's collapse traces to February 23, 2026, when Gossamer announced PROSERA's topline results: seralutinib missed its primary six-minute walk distance endpoint, showing a placebo-adjusted improvement of 13.3 meters at Week 24 (p=0.032) against a pre-specified significance threshold of p=0.025. Shares fell roughly 80% in the aftermath, according to securities-litigation trackers, and multiple law firms subsequently announced investigations or class-action filings over the company's prior disclosures. The July FDA update reversed some of that pessimism by suggesting the near-miss wouldn't automatically block a filing, but the stock remains far below pre-crash levels, and a Nasdaq bid-price deficiency notice (issued April 8, with an October 5, 2026 compliance deadline) has forced a reverse split, a mechanical fix that doesn't change underlying value but signals continued distress.

Bull Case

Bulls note the FDA didn't reject the PROSERA data outright, it explicitly allowed a filing path using one Phase 3 study plus confirmatory Phase 2 evidence, which is not guaranteed but is a real regulatory opening in a disease area (PAH) with significant unmet need. Reacquiring full seralutinib rights from Chiesi means Gossamer keeps the "substantial majority" of the drug's Economics if it's approved, rather than splitting profits. The debt exchange removed over $115 million of near-term convertible-note overhang, and R&D spending has already dropped sharply as trial costs wind down, extending the runway modestly.

Bear Case

The core problem is unresolved: PROSERA missed its primary endpoint, and the FDA's "review issue" framing means the agency could still decide, after a full review of the filing, that the efficacy data don't support approval, the risk has been deferred, not eliminated. Cash runway into only Q1 2027 sits uncomfortably close to a Q3 2027 potential approval decision, all but guaranteeing further dilution or financing on unfavorable terms for a stock already near record lows. Goldman Sachs has suspended its rating, price target, and estimates on Gossamer citing going-concern uncertainty, while Barclays maintains an Underweight rating with a $0.28 target, flagging dilution risk from the note exchange. A liver-enzyme safety signal (13% transaminase elevations versus 1% on placebo) adds another wrinkle for regulators. Pending Shareholder litigation over the PROSERA disclosures is an added overhang.

What Could Move the Stock Next?

The most immediate catalyst is the actual NDA submission, expected in September 2026, followed by an FDA filing-acceptance decision roughly 60 days later. Execution and terms of the reverse stock split, progress toward the October 5 Nasdaq compliance deadline, any new Capital raise, and developments in the pending securities litigation are all near-term watch items. Longer term, the Q3 2027 approval decision, if the filing is accepted, is the defining event for the company's fate.

A September Deadline That Will Define GOSS

Gossamer Bio sits at an unusually binary juncture: a regulatory reprieve that revived hope for seralutinib's approval path, set against a Balance Sheet stretched thin and a share price that reflects deep market doubt about both the science and the financing. The September NDA filing is a real, verifiable near-term event, but it resolves only the first of several hurdles, filing acceptance, cash needs, and eventual FDA review, that stand between Gossamer and a marketed PAH therapy. Investors watching this name are effectively Underwriting execution risk on several fronts simultaneously, with no single data point yet in hand to settle the debate.